AI-driven digital engineering company, Quantiphi, has launched Digital Animal Replacement Technology (DART). The company claims the technology offers a humane, accurate alternative to animal testing for drug discovery, manufacturing, and pre-clinical trials.

In December 2022, US President Biden signed the FDA Modernization Act 2.0, opposing the Federal Food, Drug, and Cosmetics Act of 1938, which required animal testing for every new drug development protocol. Consequently, new approach methodologies are being brought to the forefront for drug testing.

The Humane Society estimates that more than 50 million animals are used in experiments each year in the US. In 2019, a study estimated that 89% of novel drugs fail human clinical trials, with approximately one-half of these relating to unanticipated human toxicity.

US-based Quantiphi, concerned with delivering artificial intelligence (AI) solutions that ensure safety, security, and social equity, developed DART, which uses ethically sourced human stem cells, a digital workstation, and artificial intelligence to predict drug safety based on stem cell-drug interactions.

Global Leader in Healthcare and Life Science at Quantiphi, Bruno Nardone said: “It uses advanced machine learning and computer vision algorithms, data analytics, and a well-developed wet-lab infrastructure to accelerate drug discovery while ensuring safety and efficacy.”

Describing the benefits of DART beyond ethics, Nardone said: “It enables early-stage decision-making, reduces cost, improves time-to-market, and it offers advantages like accelerated testing, customization based on genetic profiles, and relevance to human physiology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.